PNC-27: a cancer peptide that has never been tested in patients

PNC-27 is an experimental peptide that kills a range of human cancer cells in the lab while leaving normal cells alone, and it has shrunk tumours or slowed leukaemia in a handful of mouse experiments. It has never been tested in a human clinical trial. The only published human report describes a patient with end-stage cancer who bled heavily after receiving it abroad, and the US Food and Drug Administration has told cancer patients not to use it [9,10].

What it is

PNC-27 is a 32-amino-acid lab-made peptide with two halves. The first half copies residues 12 to 26 of p53, the well-known tumour-suppressor protein, specifically the stretch p53 uses to grip a partner protein called HDM-2 (the human version of MDM2). The second half is a “membrane residency” sequence, borrowed from a cell-penetrating peptide, which helps it sit in and cross cell membranes [1,2].

The developers, a group centred on SUNY Downstate in Brooklyn, propose a specific mechanism. Many cancer cells, they report, carry HDM-2 on their outer membrane, whereas normal cells mostly don't. PNC-27 latches onto that surface HDM-2, the complexes assemble into rings, and the rings punch pores in the membrane so the cell bursts. This is necrosis (the cell ruptures) rather than apoptosis (orderly self-destruction) [1,2]. If that's right, it would explain why the peptide seems to spare normal cells. It would also mean the peptide doesn't need a working p53 pathway inside the cancer cell, which is useful because many cancers have lost it.

That mechanism rests on cell experiments, and almost all of them come from one research group whose senior members are inventors on PNC-27 patents [2].

The human evidence

There isn't any, in the sense that matters. We found no published clinical trial of PNC-27 in people: no phase 1 safety study, no dosing study, no efficacy trial.

What does exist is one case report, presented as a conference abstract at the American College of Gastroenterology meeting in 2017 [9]. A 46-year-old woman with end-stage metastatic cervical cancer, who had run out of standard options in the US, travelled to Mexico for PNC-27 infusions. Two days after an infusion she began vomiting large amounts of blood and bleeding from her stomas. Endoscopy found a 2 cm gastric ulcer; despite endoscopic treatment and repeated transfusions the bleeding continued, and she died after moving to comfort care [9].

The authors were careful: they wrote that causation was difficult to prove, and a gravely ill patient after heavy chemotherapy and major surgery could bleed for many reasons. They also noted that PNC-27 was being marketed online as a non-toxic potential cure, and that safety data were “virtually non-existent” [9]. A single case can't show the peptide caused the bleed. It does show that people are already receiving it, outside any trial, when nobody has measured what it does in a human body.

What the lab and animal work shows

Everything below is cell culture or mice. None of it tells you whether PNC-27 would shrink a tumour in a person, what dose would be needed, or what it would do to the rest of the body.

Cells in a dish

• Mechanism paper, 2010. The group found HDM-2 in the membranes of several cancer cell lines but not in several untransformed lines. When they engineered normal breast cells to display HDM-2 on their surface, those cells became vulnerable to the peptide [1].
• Leukaemia lines. PNC-27 killed nearly 100% of K562 leukaemia cells, which have no p53 at all, while a control peptide and mouse white blood cells were unaffected [3]. In three acute myeloid leukaemia lines, it bound surface HDM-2 and caused necrosis within four hours [4].
• Tumour cells from patients. Cells taken from two women's ovarian tumours and grown in the lab died in a dose-dependent way, as did chemotherapy-resistant ovarian lines [5]. Only two tumours were tested, and no patient received the peptide.
• Cervical cancer, 2025. The peptide killed a squamous cervical cancer line (IC50 12.4 μM) but not a normal cervical line [6].
• Imaging the pores, 2022. Electron microscopy showed ring-shaped structures containing both PNC-27 and HDM-2 at pores in treated cancer-cell membranes, and none in treated normal fibroblasts [2].

These are clean, consistent results. They're also the sort of result that many compounds produce in culture and then lose in animals or people, because a dish has no liver, no kidneys, no immune system and no blood to dilute or break down a peptide before it reaches a tumour.

Mice

Two sets of animal experiments stand out, and neither is quite the clinical picture.

A 2006 study tested PNC-28, a shorter sister peptide, not PNC-27 itself. Given into the abdomen of nude mice at the same time as rat pancreatic cancer cells were transplanted there, it destroyed the tumours; given after tumours had grown at a distant site, it shrank them briefly before they grew back more slowly than with a control peptide [7]. Treating tumours at the moment they're implanted is far easier than treating established cancer.

The most interesting paper comes from outside the developer group. Researchers at City of Hope in California found surface HDM-2 on human and mouse acute myeloid leukaemia cells, including leukaemia stem cells, but not on normal blood stem cells [8].

The study was independent in authorship, but a company, Oncolyze Inc., supplied PNC-27 and the control peptides [8]. The doses were given by injection into the abdomen of mice at tens of milligrams per kilogram per day. Nothing in it establishes a safe or effective dose for a person, and mouse leukaemia models are a long way from treating a patient's relapsed disease.

Safety and side effects

Nothing systematic is known. There are no human pharmacokinetic data, no dose-finding study and no toxicology programme in the published literature. The mouse leukaemia paper checked for damage to normal blood formation and didn't find it [8], which is one organ system in one species over two weeks.

Two real-world signals point the other way. The 2017 case report of fatal gastrointestinal bleeding after infusions [9] can't establish cause, but it's the only human outcome on record. And in January 2017 an FDA laboratory found the bacterium Variovorax paradoxus in a PNC-27 solution sold for inhalation, prompting the agency to warn that contaminated products could cause serious, potentially life-threatening infections, especially in people with weakened immune systems [10]. People having cancer treatment often fall into exactly that group.

Legal and regulatory status

PNC-27 isn't approved as a medicine anywhere we could find. The FDA stated that it has not evaluated or approved PNC-27 as safe and effective to treat any disease, including any form of cancer, and urged patients not to buy or use it, noting it was marketed in forms including nebulised solutions, intravenous solutions and suppositories [10]. It has no UK marketing authorisation, and it has never entered the clinical-trial pipeline that would be needed to get one.

Why the online claims don't hold up

You'll see PNC-27 described as a targeted cancer therapy that spares healthy cells. That description comes almost word for word from the cell-culture papers, where it's reasonably accurate for cells in a dish. Stretching it to “treats cancer” skips every step drug development exists to test: whether enough intact peptide survives in the blood to reach a tumour, whether it gets into solid tumours at all, what it does to normal tissues that may carry some surface HDM-2, what dose works, and whether any of that adds up to people living longer. For PNC-27, none of those questions has been asked in humans.

There's also a gap between the papers and the products. The research uses a defined synthetic peptide checked for purity, tested at known concentrations. What's sold online comes in nebulisers, drips and suppositories [10], none of which match anything tested in the lab or in mice, and at least one batch tested by the FDA was contaminated with bacteria. Even a reader who took the cell data at face value would have no way of knowing whether a given vial contains the same molecule, at the stated amount, free of contamination.

What we still don’t know

• Whether PNC-27 is safe to give to a person at any dose.
• Whether enough of it survives in human blood, and reaches tumours, to matter.
• Whether the surface-HDM-2 finding holds across real tumours from many patients, not just cell lines and two ovarian samples.
• Whether any group without a financial stake can reproduce the solid-tumour results.
• What caused the bleeding in the one published human case.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR×Proper Protocols